Generative Protein Design Engineering

Generate novel, stable protein candidates for biologics, enzymes, and vaccines in weeks, not years. We engineer sequences with optimized binding affinity, solubility, and immunogenicity profiles, de-risking your preclinical pipeline. Learn more about our approach to AI-driven drug discovery.

Design enzymes with enhanced catalytic activity, thermal stability, and substrate specificity for green chemistry and biomanufacturing. Our generative workflows create variants tailored to your process conditions, delivering measurable improvements in yield and efficiency. Explore our specialized generative AI for enzyme engineering.

Create entirely new protein-based biosensors and diagnostic reagents with high specificity and low cross-reactivity. We generate binding domains for novel epitopes or non-immunogenic tags, enabling next-generation point-of-care and lab-based assays.

Shift from expensive, iterative wet-lab screening to AI-driven in silico design. Our platform prioritizes synthesizable, expressible sequences with high predicted functionality, dramatically reducing the number of physical experiments required for validation.

Secure strong, defensible intellectual property with protein sequences that are novel, non-obvious, and have demonstrable utility. Our generative models explore vast, untapped regions of protein space to deliver compositions not found in nature.

Bridge the gap between computational design and physical validation. We provide integrated pipelines from sequence generation to in silico characterization (folding, docking, stability) and partner with CROs for expression and functional testing, ensuring a smooth transition to development.

De novo generation of stable, high-affinity antibody candidates, cytokine variants, and enzyme therapeutics with optimized pharmacokinetic properties. We deliver sequences pre-validated for expression yield and structural stability, reducing early-stage discovery cycles from months to weeks.

Learn more about our approach to AI-Driven Drug Discovery Platform Development.

AI-driven engineering of enzymes for enhanced catalytic activity, thermostability, and substrate specificity in biomanufacturing, bioremediation, and green chemistry. Our models predict mutations that achieve target performance metrics, bypassing costly high-throughput screening.

This work is complemented by our dedicated Generative AI for Enzyme Engineering service.

Design of highly specific protein binders and reporters for point-of-care diagnostics, in vivo imaging, and environmental monitoring. We generate proteins with tailored binding kinetics and fusion compatibility for integration into sensor platforms.

Generation of entirely novel protein folds and scaffolds not found in nature, creating blank-slate platforms for multi-specific biologics, drug delivery vehicles, and advanced biomaterials. This unlocks functionality beyond the constraints of natural protein families.

Computational design of immunogens that elicit potent and broad neutralizing antibody responses against viral pathogens and cancers. Our AI models optimize for structural mimicry of native epitopes while enhancing stability and manufacturability.

Rational design of peptides and miniproteins that disrupt pathogenic protein-protein interactions (PPIs) considered 'undruggable' by small molecules. Our generative models explore conformational space to identify tight-binding interfaces.

This often leverages insights from our Graph Neural Network Solutions for Biological Networks.